Drugs & Targets Ipsen voluntarily withdraws Tazverik in follicular lymphoma and epithelioid sarcoma March 13, 2026Vol.52 No.10
News Analysis GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Cancer Policy Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members March 06, 2026Vol.52 No.09By Claire Marie Porter and Sara Willa Ernst
Cancer Policy House member introduces bill to increase funding for MCD testing of firefighters March 06, 2026Vol.52 No.09By Sara Willa Ernst
In Brief Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition March 06, 2026Vol.52 No.09
In Brief Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute March 06, 2026Vol.52 No.09
In Brief Fred Hutch announces 12 recipients of the annual Harold M. Weintraub Graduate Student Award March 06, 2026Vol.52 No.09
